You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 21, December 6, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Research Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (32)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Venous Thromboembolism
 •Oncology
 •Cardiovascular System
 •Randomized Controlled Trial
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The immunomodulatory drugs thalidomide and lenalidomide recently received US Food and Drug Administration approval for the treatment of multiple myeloma.1-4 Venous thromboembolism (VTE) is a potentially serious complication associated with their use.5-8 We conducted a systematic review of thromboembolism occurring with immunomodulatory drug treatment of cancer.

Methods

We reviewed incidents of thalidomide- or lenalidomide-associated VTE among patients with cancer that were reported to the US Food and Drug Administration's MEDWATCH; reported in phase 2/3 clinical trials presented at hematology/oncology conferences in the United States, Europe, and Australia; or reported as articles published between 1998 and July 2006. Databases searched included PubMed and online abstracts for national and international hematology or oncology conferences. MeSH terms included thalidomide, lenalidomide, deep vein thrombosis, thromboembolism, and pulmonary embolism. The case definition of VTE included deep vein thromboembolism or pulmonary embolism diagnosed with vascular . . . [Full Text of this Article]

Charles L. Bennett, MD, PhD, MPP
cbenne@northwestern.edu

Cara Angelotta, BA
Division of Hematology/Oncology

Paul R. Yarnold, PhD
Department of Emergency Medicine

Andrew M. Evens, DO, MS
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Ill

Jeffrey A. Zonder, MD
Division of Hematology-Oncology
Karmanos Cancer Institute
Wayne State University
Detroit, Mich

Dennis W. Raisch, PhD
VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center
University of New Mexico
Albuquerque

Paul Richardson, MD
Division of Hematologic Malignancy
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Mass



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cancer and thrombosis: implications of published guidelines for clinical practice
Khorana
Ann Oncol 2009;20:1619-1630.
ABSTRACT | FULL TEXT  

Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Lee et al.
JNCI J Natl Cancer Inst 2009;101:1049-1057.
ABSTRACT | FULL TEXT  

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Richardson et al.
Blood 2009;114:772-778.
ABSTRACT | FULL TEXT  

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Richardson et al.
JCO 2009;27:3518-3525.
ABSTRACT | FULL TEXT  

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Johnson et al.
Blood 2008;112:4924-4934.
ABSTRACT | FULL TEXT  

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
Nalluri et al.
JAMA 2008;300:2277-2285.
ABSTRACT | FULL TEXT  

Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Kristinsson et al.
Blood 2008;112:3582-3586.
ABSTRACT | FULL TEXT  

Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
Lacy et al.
Mayo Clin Proc. 2007;82:1179-1184.
ABSTRACT | FULL TEXT  

Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.